329 related articles for article (PubMed ID: 24078983)
21. Serious adverse events with infliximab: analysis of spontaneously reported adverse events.
Hansen RA; Gartlehner G; Powell GE; Sandler RS
Clin Gastroenterol Hepatol; 2007 Jun; 5(6):729-35. PubMed ID: 17481964
[TBL] [Abstract][Full Text] [Related]
22. How to improve the safety of biologic therapy in Crohn's disease.
Ferkolj I
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
[TBL] [Abstract][Full Text] [Related]
23. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
[TBL] [Abstract][Full Text] [Related]
24. Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study.
Nyboe Andersen N; Pasternak B; Friis-Møller N; Andersson M; Jess T
BMJ; 2015 Jun; 350():h2809. PubMed ID: 26048617
[TBL] [Abstract][Full Text] [Related]
25. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.
Cottone M; Kohn A; Daperno M; Armuzzi A; Guidi L; D'Inca R; Bossa F; Angelucci E; Biancone L; Gionchetti P; Ardizzone S; Papi C; Fries W; Danese S; Riegler G; Cappello M; Castiglione F; Annese V; Orlando A
Clin Gastroenterol Hepatol; 2011 Jan; 9(1):30-5. PubMed ID: 20951835
[TBL] [Abstract][Full Text] [Related]
26. Safety profile of IBD therapeutics: infectious risks.
Afif W; Loftus EV
Gastroenterol Clin North Am; 2009 Dec; 38(4):691-709. PubMed ID: 19913209
[TBL] [Abstract][Full Text] [Related]
27. Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.
Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Churchill S; Karlson EW; Murphy SN; Kohane I; Liao KP
Aliment Pharmacol Ther; 2015 Jun; 41(11):1141-8. PubMed ID: 25864945
[TBL] [Abstract][Full Text] [Related]
28. The effects of race and socioeconomic status on immunomodulator and anti-tumor necrosis factor use among ambulatory patients with inflammatory bowel disease in the United States.
Lin KK; Sewell JL
Am J Gastroenterol; 2013 Dec; 108(12):1824-30. PubMed ID: 24300857
[TBL] [Abstract][Full Text] [Related]
29. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
30. Serious infections associated with anticytokine therapies in the rheumatic diseases.
Giles JT; Bathon JM
J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118
[TBL] [Abstract][Full Text] [Related]
31. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.
Qiu Y; Mao R; Chen BL; Zhang SH; Guo J; He Y; Zeng ZR; Ben-Horin S; Chen MH
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1359-1372.e6. PubMed ID: 28232073
[TBL] [Abstract][Full Text] [Related]
32. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
[TBL] [Abstract][Full Text] [Related]
33. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection.
Ben-Horin S; Margalit M; Bossuyt P; Maul J; Shapira Y; Bojic D; Chermesh I; Al-Rifai A; Schoepfer A; Bosani M; Allez M; Lakatos PL; Bossa F; Eser A; Stefanelli T; Carbonnel F; Katsanos K; Checchin D; Miera IS; Chowers Y; Moran GW;
Clin Gastroenterol Hepatol; 2009 Sep; 7(9):981-7. PubMed ID: 19523534
[TBL] [Abstract][Full Text] [Related]
34. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
35. Immunomodulator use does not prevent first loss of response to anti-tumour necrosis factor alpha therapy in inflammatory bowel disease: long-term outcomes in a real-world cohort.
Varma P; Rajadurai AS; Holt DQ; Devonshire DA; Desmond CP; Swan MP; Nathan D; Shelton ET; Prideaux L; Sorrell C; Rusli F; Crantock LRF; Dev A; Ratnam DT; Pianko S; Moore GT
Intern Med J; 2019 Jun; 49(6):753-760. PubMed ID: 30381884
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease.
Osterman MT; Haynes K; Delzell E; Zhang J; Bewtra M; Brensinger CM; Chen L; Xie F; Curtis JR; Lewis JD
Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1293-1301.e5; quiz e70, e72. PubMed ID: 25724699
[TBL] [Abstract][Full Text] [Related]
37. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
[TBL] [Abstract][Full Text] [Related]
38. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy.
Sherman M; Tsynman DN; Kim A; Arora J; Pietras T; Messing S; St Hilaire L; Yoon S; Decross A; Shah A; Saubermann L
J Dig Dis; 2014 Apr; 15(4):174-9. PubMed ID: 24373601
[TBL] [Abstract][Full Text] [Related]
39. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
[TBL] [Abstract][Full Text] [Related]
40. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis.
Targownik LE; Tennakoon A; Leung S; Lix LM; Singh H; Bernstein CN
Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1061-1070.e1. PubMed ID: 28238957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]